文献速递艾滋病与性传播感染

新型冠状病毒肺炎(COVID-19)对美国人类免疫缺陷病毒(HIV)暴露前预防处方的影响——时间序列分析

Impact of Coronavirus Disease 2019 (COVID-19) on Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Prescriptions in the United States-A Time-Series Analysis.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该研究利用2017年1月至2021年3月全国药房数据库,构建中断时间序列模型预测无疫情时的HIV暴露前预防(PrEP)处方量。结果显示2020年3月15日至2021年3月31日观察到的PrEP处方为825 239张,较预测的1 058 162张减少22.0%(95% CI:19.1-24.8%);新用户为125 793人,较预测的167 720人减少25.0%(95% CI:20.9-28.9%)。疫情对年轻人和商业保险者影响更大,各州差异明显。

要点

  • COVID-19疫情期间PrEP处方较预测减少22.0%(95% CI:19.1-24.8%)
  • 同期新PrEP用户较预测减少25.0%(95% CI:20.9-28.9%)
  • 疫情影响在年轻人和商业保险者中更大,各州差异明显

核心结论

  • COVID-19疫情打断了美国PrEP处方原本上升的趋势,凸显在类似紧急事件中需创新干预以维持HIV预防服务可及性。

研究设计与样本

  • 研究分析2017年1月至2021年3月全国药房数据库,拟合中断时间序列模型预测无疫情时的PrEP处方和新用户数。

主要发现

  • 2020年3月15日至2021年3月31日观察PrEP处方825 239张,预测1 058 162张,减少22.0%(95% CI:19.1-24.8%)。
  • 同期观察新PrEP用户125 793人,预测167 720人,减少25.0%(95% CI:20.9-28.9%)。
  • COVID-19影响在年轻人和商业保险者中更大,各州差异明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uptake of HIV pre-exposure prophylaxis (PrEP) has been increasing in the United States since its FDA approval in 2012; however, the COVID-19 pandemic may have affected this trend. Our objective was to assess the impact of COVID-19 on PrEP prescriptions in the United States. METHODS: We analyzed data from a national pharmacy database from January 2017 through March 2021 to fit an interrupted time-series model that predicted PrEP prescriptions and new PrEP users had the pandemic not occurred. Observed PrEP prescriptions and new users were compared with those predicted by the model. Main outcomes were weekly numbers of PrEP prescriptions and new PrEP users based on a previously developed algorithm. The impact of the COVID-19 pandemic was quantified by computing rate ratios and percentage decreases between the observed and predicted counts during 15/3/2020-31/3/2021. RESULTS: In the absence of the pandemic, our model predicted that there would have been 1 058 162 PrEP prescriptions during 15/3/2020-31/3/2021. We observed 825 239 PrEP prescriptions, a 22.0% reduction (95% CI: 19.1-24.8%) after the emergency declaration. The model predicted 167 720 new PrEP users during the same period; we observed 125 793 new PrEP users, a 25.0% reduction (95% CI: 20.9-28.9%). The COVID-19 impact was greater among younger persons and those with commercial insurance. The impact of the pandemic varied markedly across states. CONCLUSIONS: The COVID-19 pandemic disrupted an increasing trend in PrEP prescriptions in the United States, highlighting the need for innovative interventions to maintain access to HIV-prevention services during similar emergencies.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Huang YLA, Zhu W, Wiener J, et al. Impact of Coronavirus Disease 2019 (COVID-19) on Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Prescriptions in the United States-A Time-Series Analysis. Clin Infect Dis. 2022. PMID: 35040928. doi:10.1093/cid/ciac038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。